# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001140361-25-024089
Filing Date
2025-06-30
Accepted
2025-06-30 07:37:57
Documents
13
Period of Report
2025-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | ef20051351_8k.htm iXBRL | 8-K | 46078
2 | EXHIBIT 2.1 | ef20051351_ex2-1.htm | EX-2.1 | 1974132
| Complete submission text file | 0001140361-25-024089.txt |  | 2533420

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
3 | XBRL TAXONOMY EXTENSION SCHEMA | bcrx-20250627.xsd | EX-101.SCH | 3865
4 | XBRL TAXONOMY EXTENSION LABEL LINKBASE | bcrx-20250627_lab.xml | EX-101.LAB | 21966
5 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | bcrx-20250627_pre.xml | EX-101.PRE | 16044
15 | EXTRACTED XBRL INSTANCE DOCUMENT | ef20051351_8k_htm.xml | XML | 4205

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 251088764
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)